{"url_path":"/sec/dmra/8-k/2026-07-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-308899-index.html","accession_number":"0001193125-26-308899","cik":"0001800315","ticker":"DMRA","issuer_name":"Damora Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800315/0001193125-26-308899-index.html","primary_entity_key":"0001800315","primary_entity_name":"Damora Therapeutics, Inc."},"word_count":165,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits\n\n \n\nExhibit\n\nDescription\n\n2.1*\n\n[Plan of Conversion.](dmra-ex2_1.htm)\n\n3.1*\n\n[Cayman Memorandum and Articles of Association.](dmra-ex3_1.htm)\n\n3.2*\n\n[Cayman Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Shares, effective July 16, 2026.](dmra-ex3_2.htm)\n\n3.3*\n\n[Cayman Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Shares, effective July 16, 2026.](dmra-ex3_3.htm)\n\n3.4*\n\n[Cayman Certificate of Designation of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Shares, effective July 16, 2026.](dmra-ex3_4.htm)\n\n10.1*\n\n[Form of Indemnification Agreement for directors and officers.](dmra-ex10_1.htm)\n\n99.1*\n\n[Press Release, issued on July 17, 2026.](dmra-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n \n\n \n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDamora Therapeutics, Inc.\n\n(Registrant)\n\n \n\n \n\n \n\n \n\nDate: July 20, 2026\n\n \n\nBy:\n\n/s/ Jennifer Jarrett\n\n \n\n \n\n \n\nJennifer Jarrett\n\n \n\n \n\n \n\nPresident and Chief Executive Officer"}